Stocks Health care KYNB
NASDAQ · Health careKyntra Bio, Inc. (KYNB)
Kyntra Bio, Inc. brought in $4.6M of revenue over the twelve months to June 30, 2026, down 37.1% from a year earlier. Net income was $183.2M, a net margin of 3,967.8%. In fiscal 2025 capital spending exceeded operating cash flow by $4.8M. At June 30, 2026 it held $50.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Kyntra Bio, Inc.
- Net worth
- Kyntra Bio, Inc. has a market value (market cap) of $15.5M at the latest share price, and shareholders' equity of -$30.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $4.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kyntra Bio, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Kyntra Bio, Inc. does
Kyntra Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KYNB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.4M | $183.5M | $45.37 | -$4.8M |
| 2024 | $29.6M | -$47.6M | -$11.89 | -$138.3M |
| 2023 | $46.8M | -$284.2M | -$72.33 | -$317.5M |
| 2022 | $140.7M | -$293.7M | -$77.78 | -$149.7M |
| 2021 | $235.3M | -$290M | -$77.78 | -$87.4M |
| 2020 | $176.3M | -$189.3M | -$52.27 | $77.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KYNB ranks in Health care
Latest SEC filings
What Kyntra Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026
- October 1, 2026Executive or director change8-KKyntra Bio appointed Andrew E. Singer to its board of directors, announced the resignation of Maykin Ho, and renewed its severance agreement with CEO Thane Wettig.
- August 31, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026
- June 16, 2026
- June 9, 2026Other event 8-K
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 36% to $3.7M versus the same quarter last year; diluted EPS -$3.76 versus $1.15.
Insider trades
What the people running Kyntra Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 6, 2026 | Wettig ThaneCEO, Director | Shares withheld for tax | 209 | $1.8K |
| September 6, 2026 | DeLucia DavidChief Financial Officer | Shares withheld for tax | 22 | $188.1 |
| June 6, 2026 | Wettig ThaneCEO, Director | Shares withheld for tax | 198 | $1.3K |
| June 6, 2026 | DeLucia DavidChief Financial Officer | Shares withheld for tax | 52 | $348.9 |
| May 14, 2026 | Wettig ThaneCEO, Director | Bought | 2,800 | $19.9K |
| May 14, 2026 | Wettig ThaneCEO, Director | Bought | 2,800 | $19.9K |
| March 6, 2026 | Wettig ThaneCEO, Director | Shares withheld for tax | 277 | $1.9K |
| March 6, 2026 | DeLucia DavidChief Financial Officer | Shares withheld for tax | 60 | $410.4 |
Who owns KYNB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.88% | August 14, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 31,151 shares in total, about $119K at the last price.
| Holder | Shares |
|---|---|
| Wettig ThaneCEO, Director | 26,796 |
| DeLucia DavidChief Financial Officer | 4,355 |
Questions about KYNB
What does Kyntra Bio, Inc. do?
Kyntra Bio, Inc. is a company in the Health care sector, listed on NASDAQ as KYNB. Its shares trade on NASDAQ under the ticker KYNB.
What is Kyntra Bio, Inc.'s net worth?
Kyntra Bio, Inc. has a market value (market cap) of $15.5M at the latest share price, and shareholders' equity of -$30.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kyntra Bio, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $183.2M on revenue of $4.6M, a net margin of 3,967.8%.
How much revenue does Kyntra Bio, Inc. make?
Over the twelve months to June 30, 2026 Kyntra Bio, Inc. reported revenue of $4.6M. That is 37.1% less than a year earlier.
When did Kyntra Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from October 6, 2026.
When is Kyntra Bio, Inc.'s next earnings report?
Kyntra Bio, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare KYNB with
Follow KYNB
Get an email when Kyntra Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kyntra Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.